Skip to main content
Explore URMC

menu

Study of Peptide Vaccine in Treating Patients with Newly Diagnosed Plasma Cell Leukemia

Research Question:
What is the safety of a peptide vaccine (called SVN53-67/M57-KLH) in treating patients with newly diagnosed multiple myeloma (plasma cell leukemia) who are receiving chemotherapy?

Basic Study Information

Purpose:
This study looks at treating patients with newly diagnosed multiple myeloma (plasma cell leukemia) who are receiving lenalidomide maintenance therapy, a kind of maintenance chemotherapy. Specifically, this study will look at the safety of SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant together with sargramostim. This peptide vaccine may help the body build an effective immune response to kill certain cancer cells. Incomplete Freund's adjuvant may help stimulate the body's immune response to the vaccine treatment. Sargramosti may increase the production of blood cells. Lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant and sargramostim before or after the start of lenalidomide maintenance therapy may be a better treatment for multiple myeloma.

Location: University of Rochester Medical Center
Study Reference #: UMMY18067

Lead Researcher (Principal Investigator)

Lead Researcher: Brea Lipe

Study Contact Information

Study Coordinator: Stephanie Short
Phone: (585) 276-7885
Email: Stephanie_Short@URMC.Rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search